Table 3.
Risk factors for predicting IVR following RUN for UTUC in 220 patients.
| Characteristic | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | |
| Laterality | ||||
| Left | Reference | Reference | ||
| Right | 0.70(0.42,1.17) | 0.168 | 0.93(0.53,1.64) | 0.809 |
| Multifocality | ||||
| Single | Reference | Reference | ||
| Multiple | 2.06(1.19,3.57) | 0.010 | 1.15(0.61,2.16) | 0.671 |
| Pathologic stage | ||||
| pT1 | Reference | Reference | ||
| pT2 | 1.88(1.03,3.42) | 0.039 | 2.16(1.14,4010) | 0.018 |
| pT3 | 1.32(0.63,2.75) | 0.461 | 0.77(0.34,1.74) | 0.531 |
| pT4 | 2.61(0.91,7.52) | 0.075 | 1.01(0.32,3.23) | 0.981 |
| Tumor size | 1.11(0.95,1.29) | 0.178 | 1.16(0.99,1.37) | 0.073 |
| Margin Status | ||||
| Negative | Reference | Reference | ||
| Positive | 4.94(1.96,12.43) | 0.001 | 7.50(2.44,23.08) | <0.001 |
| Urine pathology | ||||
| Negative | Reference | Reference | ||
| Atypical | 2.98(1.47,6.05) | 0.004 | 2.79(1.32,5.88) | 0.007 |
| Tumor Cell | 7.06(3.40,14.70) | <0.001 | 8.12(3.63,18.15) | <0.001 |
| Hydronephrosis | ||||
| ≤2cm | Reference | Reference | ||
| >2cm | 1.93(1.15,3.23) | 0.013 | 1.45(0.84,2.51) | 0.18 |
| Adjuvant Chemotherapy | ||||
| No | Reference | Reference | ||
| Yes | 0.26(0.14,0.48) | <0.001 | 0.20(0.10,0.38) | <0.001 |
| NLR | 1.08(0.99,1.18) | 0.054 | 0.98(0.88,1.10) | 0.742 |
| LMR | 0.89(0.75,1.05) | 0.167 | 0.94(0.77,1.14) | 0.511 |
| URS | ||||
| No URS | Reference | Reference | ||
| 1-Session | 1.15(0.42,3.14) | 0.782 | 0.72(0.24,2.19) | 0.562 |
| 2-Session | 1.93(1.08,3.46) | 0.027 | 1.98(1.08,3.65) | 0.028 |
UTUC, upper urinary tract cancer; IVR, intravesical recurrence; RUN, radical nephroureterectomy; URS, ureteroscopy; NLR, neutrophil-to-lymphocyte ratio; LMR, lymphocyte-to -monocyte ratio; HR, hazard ratio; CI, confidence interval.